# FDA 483 - Ulhas M. Nadgir, M.D. - October 10, 2024

Source: https://www.globalkeysolutions.net/records/483/ulhas-m-nadgir-md/debfed98-2dbc-4e2d-9b64-68e27716e151

> FDA 483 for Ulhas M. Nadgir, M.D. on October 10, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ulhas M. Nadgir, M.D.
- Inspection Date: 2024-10-10
- Product Type: drugs
- Office Name: San Francisco District Office
- Summary: An FDA inspection of Ulhas M. Nadgir, M.D., Clinical Investigator in Sacramento, CA, from October 7-10, 2024, revealed a significant deviation from the investigational plan. The primary concern was the enrollment and treatment of a study subject who met an exclusion criterion, indicating a failure to conduct the investigation in accordance with the signed statement of investigator.

## Related Officers

- [FDA_PERSONNEL](https://www.globalkeysolutions.net/people/stephanie-barragan/fc1bc901-1467-4fdd-bee3-f87f2db3a1fa)

Company: https://www.globalkeysolutions.net/companies/ulhas-m-nadgir-md/f7c33197-3df2-4285-a7c2-846d46e2741e

Office: https://www.globalkeysolutions.net/offices/san-francisco-district-office/6f838e9c-aae1-4665-9c46-a51d43be02df